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Background. Diazabicyclooctanes (DBOs) inhibit Class A, C and some Class D β-lactamases. A few 29 
also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' 30 
effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with 31 
cefepime. Methods. CLSI agar dilution MICs were determined with cefepime/zidebactam in a 32 
chequerboard format. Bactericidal activity was also measured. Results. Zidebactam MICs were <2 33 
mg/L (mostly 0.12-0.5 mg/L) for most Escherichia coli, Klebsiella, Citrobacter and Enterobacter spp., 34 
but were >32 mg/L for Proteeae, most Serratia and a few E. coli, Klebsiella and 35 
Enterobacter/Citrobacter. The antibacterial activity of zidebactam dominated chequerboard studies for 36 
Enterobacteriaceae, but potentiation of cefepime was apparent for zidebactam-resistant isolates with 37 
class A and C enzymes, illustrating -lactamase inhibition.  Overall, cefepime/zidebactam inhibited 38 
almost all Enterobacteriaceae with AmpC, ESBL, K1, KPC and OXA-48-like -lactamases at 1+1 39 
mg/L and also 29/35 isolates with metallo-carbapenemases, including several resistant to zidebactam 40 
alone. Zidebactam MICs for 36/50 Pseudomonas aeruginosa were 4-16 mg/L, and majorities of 41 
AmpC, metallo--lactamase-producing and cystic fibrosis isolates were susceptible to 42 
cefepime/zidebactam 8+8 mg/L. Zidebactam MICs for Acinetobacter baumannii and 43 
Stenotrophomonas maltophilia were >32 mg/L; potentiation of cefepime was frequent for S. 44 
maltophilia, but minimal for A. baumannii. Kill curve results largely supported MICs. Conclusion. 45 
Zidebactam represents a second triple action DBO following RG6080, with lower MICs for 46 
Enterobacteriaceae and P. aeruginosa.  Clinical evaluation of cefepime/zidebactam must critically 47 
evaluate the reliance that can be placed on this direct antibacterial activity and on the enhancer effect 48 
as well as -lactamase inhibition. 49 
50 
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Introduction  51 
Diazabicyclooctanes (DBOs) are among the most promising new -lactamase inhibitors.1 The first 52 
member of the class, avibactam, is already marketed in combination with ceftazidime and is under 53 
investigation combined with aztreonam1,2 whilst a second analogue, relebactam, has undergone is 54 
now in phase III development combined with imipenem-cilastatin.3 Avibactam and relebactam act 55 
solely as inhibitors of class A, C and some class D lactamases at clinical concentrations, though 56 
avibactam does directly inhibit the growth of many Escherichia coli strains at concentrations a little 57 
above the  4 mg/L routinely used in MIC tests. Avibactam MICs for other species are higher.  58 
 Some developmental DBOs have greater direct antibacterial activity. RG6080/OP0595 (Meiji, 59 
Fedora, Roche) not only has similar -lactamase inhibitory activity to avibactam, but also has MICs of 60 
around 1-4 mg/L for most E. coli, Klebsiella, Enterobacter and Citrobacter spp., contingent on 61 
attacking penicillin-binding protein (PBP)2.4,5 Proteeae and non-fermenters are resistant, with MICs 62 
>32 mg/L. Like mecillinam6 – another PBP2-targeting agent – RG6080 also synergises or 'enhances' 63 
the activity of PBP3-targeted -lactams against many E. coli, Klebsiella spp. and Enterobacter spp., 64 
regardless of whether these produce -lactamases. The enhancer effect is retained against some 65 
strains and mutants with resistance to the antibacterial action of OP0595 and these additional 66 
activities allow -lactam-RG6080 combinations to achieve in-vitro activity against many 67 
Enterobacteriaceae with metallo--lactamases (MBLs), even though these evade inhibition by 68 
DBOs.4,5,7    69 
 In the present study we characterised the activity of a second DBO with direct antibacterial 70 
activity, zidebactam (Wockhardt, WCK 5107, figure 1), tested in combination with cefepime, which is 71 
its intended clinical partner lactam (see e.g. https://clinicaltrials.gov/ct2/show/NCT02707107). The 72 
cefepime/zidebactam combination is also known by the code number WCK 5222. 73 
 74 
Materials and methods 75 
Isolates 76 
Isolates (n=269) were reference submissions to Public Health England from UK diagnostic 77 
laboratories, or were collected in during resistance surveys. The distribution of resistance 78 
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mechanisms by species is shown in Table 1.  Isolates were identified using API20E or API20NE 79 
strips (bioMerieux, Marcy l'Etoile, France) or by MALDI-ToF mass spectroscopy (Maldi-Biotyper, 80 
Bruker, Bremen, Germany), with the exception that  Acinetobacter baumannii were identified by PCR 81 
detection of blaOXA-51-like.8 Carbapenemase genes were identified by PCR or sequencing;9 other 82 
mechanisms were inferred from phenotype and (where available) genotype data.  83 
  84 
Susceptibility testing 85 
MICs of cefepime (US Pharmacopoeial Convention, Rockville, USA) were determined by CLSI agar 86 
dilution10 in a chequerboard format with zidebactam (Wockhardt, Aurangabad, India) included at 87 
0.06-8 mg/L. Comparator antibiotics were tested in parallel and comprised: piperacillin (Sigma-88 
Aldrich, Poole, UK) with 4 mg/L tazobactam (Wockhardt), ceftazidime (Sigma-Aldrich) alone and with 89 
4 mg/L avibactam (Wockhardt), also meropenem (Sequoia Research Products, Pangbourne, UK). 90 
 91 
Killing curves 92 
Bacteria were grown overnight, with shaking, in Mueller-Hinton Broth at 37oC then diluted 1000-fold 93 
into 100 ml of fresh warm broth. Incubation was continued, with shaking, for 90 min to bring the cells 94 
into early log phase.  The cultures were then divided into 10-ml volumes and antibiotics or 95 
combinations were added, with incubation continued as before.  This point was defined as T0, and a 96 
single count was performed, representing the starting point for all curves with that strain.  Further 97 
counts were performed on all cultures at T+1h, T+2h T+4h, T+6h, T+8h (non-fermenters only) and 98 
T+24h. Counts were by the Miles and Misra method and ‘bactericidal’ is used in the classical sense, 99 
as meaning ‘causing some initial reduction in bacterial counts’, irrespective of the extent or duration 100 
these reductions. 101 
  102 
Results 103 
Antibacterial activity of zidebactam  104 
The great majority (92/102) of isolates of E. coli, Enterobacter spp. and Citrobacter spp. were 105 
susceptible to zidebactam at <1 mg/L, with 86/102 MICs clustered from 0.12 to 0.5 mg/L (Table 2). 106 
MICs for Klebsiella spp. were more bimodally distributed, with 40/58 values from 0.12-2 mg/L and 107 
16/58 at >32 mg/L.  Trailing end points and surviving colonies made reading difficult, especially with 108 
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Klebsiella spp. Zidebactam MICs also were bimodal for Serratia spp., but with most (7/10) values >32 109 
mg/L. All Proteeae (n=19) were resistant, with MICs >32 mg/L. No relationship was apparent 110 
between zidebactam MICs and the -lactamase phenotypes and genotypes for which the 111 
Enterobacteriaceae were selected for inclusion in the study. 112 
 In the case of P. aeruginosa, MICs for 36/50 isolates were in the range 4-16 mg/L, but the 113 
median values for AmpC- and MBL-producing isolates (8 mg/L) were one doubling dilution higher 114 
than for the susceptible controls (4 mg/L) and the median for the increased-efflux isolates was a 115 
further two-fold higher, at 16 mg/L. Zidebactam MICs for A. baumannii and Stenotrophomonas 116 
maltophilia universally exceeded 32 mg/L. 117 
Combination activity of cefepime/zidebactam: Enterobacteriaceae 118 
At 1 mg/L (EUCAST's susceptible breakpoint, http://www.eucast.org) unprotected cefepime inhibited 119 
only 6/33 ESBL producers, 26/35 AmpC hyperproducers, 4/5 K1 hyperproducers, 7/15 with OXA-48-120 
like enzymes, and none of those with KPC (n=30) or metallo--lactamases (MBLs, n=35) (Table 3).  121 
Addition of zidebactam increased these proportions markedly, so that cefepime/zidebactam 1+1 mg/L 122 
was active against all 33 Enterobacteriaceae with ESBLs, all 35 with hyper-produced AmpC 123 
enzymes, all five with hyper-produced K1 enzyme (n=5), all 15 with OXA-48-like carbapenemases, 124 
29/30 with KPC enzymes and 29/35 with MBLs.  The sole KPC isolate that was resistant to 1+1 mg/L 125 
was an Enterobacter cloacae that was inhibited by zidebactam alone at 4 mg/L and by 126 
cefepime/zidebactam at 8+2 or 4+4 mg/L.  Much of this gain in spectrum reflected the direct 127 
antibacterial activity of zidebactam, which inhibited many E. coli, Klebsiella, Enterobacter and 128 
Citrobacter spp. isolates at 1 mg/L (above, Table 2).   129 
The lactamase inhibitory activity and enhancer effects of zidebactam became evident for the 130 
minority of Enterobacteriaceae with high MICs for the DBO, taken here as MIC >16 mg/L, which are 131 
line-listed in Table 4.  Strong, dose-dependent synergy was seen for all zidebactam-resistant 132 
Enterobacteriaceae isolates with class A lactamases, including ESBLs (which were mostly CTX-M 133 
types based on higher MICs for cefotaxime than ceftazidime) and KPC types, with cefepime MICs of 134 
2 to >256 mg/L reduced below 1 mg/L even by zidebactam at 1 mg/L or less. The sole 'zidebactam-135 
resistant' (MIC >32 mg/L) representative with an AmpC enzyme (S. marcescens SE01046) had only 136 
intermediate resistance to cefepime, with an MIC of 2 mg/L reduced to <0.03 mg/L by zidebactam at 137 
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1 mg/L.  Good cefepime/zidebactam synergy was seen for two zidebactam-resistant isolates with 138 
OXA-48 carbapenemase, but this oxacillinase has little activity against cefepime11 and it is most likely 139 
that the synergy reflected inhibition of co-produced ESBLs, which were not identified in this study.  140 
Potentiation of cefepime by zidebactam was variable for the zidebactam-resistant metallo-141 
carbapenemase producers, being at least eight-fold for two K. pneumoniae, (H113980340 and 142 
H112240413) one Morganella morganii (H092540314) and one Providencia stuartii (H124880510), all 143 
of which were susceptible to cefepime/zidebactam at 2+1 mg/L, but weak or absent for all three P. 144 
rettgeri (H123140552, H123560843 and H124880511) and the one E. coli (H130680324) where the 145 
cefepime/zidebactam MIC remained >64+8 mg/L.  146 
Ceftazidime-avibactam, tested as a comparator, was active against all ESBL, K1, AmpC, OXA-48 147 
and KPC strains at its 8+4 mg/L EUCAST and FDA breakpoint. Its MICs were higher than for 148 
cefepime/zidebactam, largely owing to the lack of direct antibacterial activity by avibactam; more 149 
critically, almost all (33/25) MBL producers were resistant to ceftazidime/avibactam, even at 8+4 150 
mg/L. The other comparators had very limited activity against this highly resistant strain collection.  151 
Unprotected ceftazidime was only active against control strains, K1-enzyme-hyperproducing K. 152 
oxytoca and those isolates that had OXA-48-like enzymes but lacked ESBLs.  Non-susceptibility 153 
rates to piperacillin/tazobactam (8+4 mg/L) exceeded 90% among isolates with AmpC, K1, OXA-48-154 
like, KPC enzymes of MBLs; meropenem resistance was near universal among the MBL- and KPC- 155 
producing isolates, though MICs for many with OXA-48-like enzymes remained around the CLSI and 156 
EUCAST susceptible breakpoints of 1 and 2 mg/L. 157 
 158 
Combination activity of cefepime/zidebactam: Non-fermenters 159 
At 8 mg/L, the antibacterial activity of zidebactam dominated combination results for P. aeruginosa, 160 
with 33/50 isolates inhibited by the DBO alone (Table 2).  Largely owing to this, 9/10 isolates with 161 
derepressed AmpC, 8/10 with MBLs, 8/10 with up-regulated efflux and 9/10 cystic fibrosis isolates 162 
were susceptible to cefepime/zidebactam at 8+8 mg/L.   Even at 4 mg/L, zidebactam increased the 163 
proportion of strains counting as susceptible to cefepime (MIC <8 mg/L) from 2/10 to 8/10 for AmpC 164 
hyperproducers, 2/10 to 6/10 for efflux strains and from 0/10 to 4/10 for cystic fibrosis isolates, 165 
although 9/10 MBL producers remained resistant.  166 
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 Cefepime MICs for A. baumannii isolates with OXA carbapenemases were mostly reduced 167 
by one doubling dilution by zidebactam at 4 or 8 mg/L, with modal values falling from 32 to 16 mg/L 168 
(Table 2); MICs for susceptible controls or those with NDM MBLs were not reduced.  MICs for S. 169 
maltophilia isolates were reduced by zidebactam: without the DBO only 2/10 isolates were 170 
susceptible to cefepime at 8 mg/L but this proportion rose to 7/10 with zidebactam present at 4 or 8 171 
mg/L.   172 
 173 
Killing curves 174 
Killing curves were determined with two isolates each of K. pneumoniae, E. coli and P. aeruginosa, 175 
all producing NDM metallo-carbapenemases. In each case, the test strains per species were chosen 176 
to include one susceptible to zidebactam and one resistant, though the differential was much greater 177 
in the Enterobacteriaceae pairs than for the P. aeruginosa (see figure 2 and its legend). A single A. 178 
baumannii strain with OXA-23 carbapenemase was also tested; this, like all members of its species, 179 
was highly resistant to zidebactam.  Cefepime MICs were >256 mg/L for all these organisms. 180 
Both the zidebactam-susceptible (H113840625 MIC 0.25 mg/L, panel 2a) and –more surprisingly- 181 
the zidebactam-resistant (H113980340, MIC >32 mg/L, panel 2b) NDM K. pneumoniae were killed by 182 
zidebactam at 4 mg/L, though the extent of killing was reduced for the resistant organism (l.5 log 183 
maximum after 4 h exposure versus 3 log). The cefepime/zidebactam combinations (1+4 and 8+4 184 
mg/L) combinations achieved 3-4 log kills for both organisms and it is notable that the zidebactam-185 
resistant K. pneumoniae H113980340 was likewise susceptible to cefepime/zidebactam 186 
combinations in MIC tests (Table 4).  For the two NDM-positive E. coli (H131020913, zidebactam 187 
MIC 0.25, panel 2c and H130680324 MIC 16 mg/L panel 2d), killing simply tracked MICs. Thus, for 188 
the zidebactam-susceptible organism, zidebactam and its cefepime combinations achieved extensive 189 
killing whereas, for the resistant strain, neither zidebactam nor its combinations achieved significant 190 
kill at the concentrations studied. Corresponding with this result, and unlike for K. pneumoniae 191 
H113840625, there was no hint of an enhancer effect for cefepime/zidebactam in MIC combination 192 
studies for this E. coli strain (Table 4).   193 
Zidebactam MICs were 8 and 32 mg/L for the two NDM-positive P. aeruginosa strains 194 
(H130680310, panel 2e/2g and H131800691 panel 2f/2h, respectively). There was some suppression 195 
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of growth for the more susceptible strain with zidebactam alone at 8 mg/L or cefepime/zidebactam 196 
16+8 mg/L, whereas the more resistant strain was unaffected.    A 2 - 4 log bactericidal effect was 197 
achieved within 8h for both strains with cefepime/zidebactam at higher concentrations (panels g and 198 
h), though only once the zidebactam was present at MIC (32 mg/L).   The A. baumannii strain, 199 
H104940508, with OXA-23 enzyme, was highly resistant to zidebactam (MIC >32 mg/L); 200 
cefepime/zidebactam 8+4 mg/L had little effect, but cefepime/zidebactam 16+8 did achieve 201 
bacteriostasis, a result in keeping with the MIC of 32+8 mg/L. 202 
In most cases where cefepime/zidebactam achieved substantial killing there was overnight re-203 
growth.  Nevertheless, where examined, the organisms remained susceptible in repeat MIC tests with 204 
cefepime/zidebactam and did not represent resistant mutants. 205 
Discussion  206 
Zidebactam represents a second DBO with multiple activities, acting not only as a lactamase 207 
inhibitor but also as a direct antibacterial and exerting an enhancer effect with PBP3-targeting -208 
lactams. Key differences from RG6080 are (i) that the MICs of zidebactam for susceptible 209 
Enterobacteriaceae are lower, typically falling into the 0.12-0.5 mg/L range rather than 1-4 mg/L and 210 
(ii) that zidebactam alone inhibited many P. aeruginosa at 4-8 mg/L whereas MICs of 211 
OP0595/RG6080 consistently exceed 32 mg/L for this species.   Proteeae, most Serratia, A. 212 
baumannii and S. maltophilia remained resistant, exactly as with RG6080.  The antibacterial activity of 213 
zidebactam is believed to depend on binding to PBP2, as with RG6080;12 it is uncertain if the lower 214 
MICs of zidebactam reflect increased target affinity, a more favourable balance of permeation and 215 
efflux, or combination of all the three or other factors.  Raised zidebactam MICs (typically 16-32 mg/L 216 
versus 4-8 mg/L) for P. aeruginosa were associated with strains known to have up-regulated efflux, 217 
indicating that the molecule does not entirely evade this mechanism.  Otherwise, however, no 218 
association was seen between the MICs of zidebactam and the resistance mechanisms for which the 219 
isolates were selected. This is in keeping with experience that raised MICs of OP0595/RG6080 were 220 
associated primarily not with ‘conventional’ -lactam resistance mechanisms, but with mutations that 221 
activate the stringent response, thereby compensating for inactivation of PBP2.13  Similar types of 222 
mutation can confer resistance to mecillinam, which also targets PBP2.14  The fact that PBP2 itself 223 
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remains unaltered means that the enhancer effect can remain even when the antibacterial activity has 224 
been lost.15 225 
 Despite its low MICs, zidebactam is better suited for development in combination than as a 226 
single agent, owing (again like OP0595/RG6080) to a high frequency of mutational resistance 227 
(Wockhardt, data on file).  Cefepime has been chosen as a partner agent, based (i) on its broad 228 
spectrum and good safety record, (ii) wide range of licensed indication, (iii) relative stability to AmpC 229 
enzymes – whi 230 
ch can mutate to resist to DBO inhibition16 and (iv) on an enhancer effect being most likely with 231 
agents, such as cefepime, that target PBP3.4 Even at 1+1 mg/L (i.e. below any likely breakpoint for a 232 
high dosage formulation) cefepime/zidebactam was active against almost all Enterobacteriaceae with 233 
AmpC, ESBL, K1, OXA-48 and KPC lactamases and the great majority (29/35) of those with MBLs. 234 
Even when zidebactam itself lacked activity, the combination retained activity against 235 
Enterobacteriaceae with class A and C lactamases, which is in keeping with kinetic data showing 236 
that zidebactam inhibits these enzymes.17 Activity was also retained against both zidebactam-237 
resistant klebsiellas with OXA-48 carbapenemase, though – given cefepime’s stability to OXA-4818 – it 238 
is most likely that this result reflected inhibition of co-produced ESBLs rather than of OXA-48 itself.  239 
Combination activity was more variable against the small number of zidebactam-resistant 240 
Enterobacteriaceae with MBLs, but the observation of strong synergy between cefepime and 241 
zidebactam for several of these organisms, notably K. pneumoniae H113980340, P. stuartii 242 
H124880510 and M. morganii H092540314 supports the view of an enhancer effect, and or the 243 
inhibition of co-produced ESBLs. Potentiation against S. maltophilia was widespread and may reflect 244 
either an enhancer effect or, more probably, inhibition of the L-2 cephalosporinase, which confers 245 
resistance to cefepime.19 246 
 The killing curves, done with pairs of NDM-carbapenemase-positive zidebactam-susceptible 247 
and -resistant E. coli, K. pneumoniae and P. aeruginosa largely supported the MIC data with the 248 
notable exceptions that zidebactam achieved some killing of the ‘zidebactam-resistant’ K. 249 
pneumoniae strain H113980340. Moreover cefepime/zidebactam achieved equally extensive killing of 250 
this strain as of its zidebactam-susceptible counterpart (H113840625), whereas there was minimal 251 
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killing of the NDM-positive zidebactam-resistant E. coli H130480324 by cefepime/zidebactam This 252 
variability recapitulates that seen in MIC studies here and previously with OP0595-resistant strains 253 
and mutants;5,7 though it should be added that zidebactam-resistance (Table 2) and the lack of an 254 
enhancer effect (Wockhardt, data on file) seem exceptional in E. coli.   Such variation may reflect the 255 
diversity of different mutations that can underlie resistance to PBP2-targeted DBOs, though precise 256 
relationships remain uncertain.  In summary, these finding further illustrate the expanding potential of 257 
the DBO class. The first member of the class to enter clinical use, avibactam, has been successfully 258 
used, combined with ceftazidime, for infections due to Gram-negative bacteria with KPC 259 
carbapenemases,20 though these were poorly represented in Phase III trials. Zidebactam and 260 
RG6080 extend this potential by adding direct antibacterial activity and an enhancer effect, contingent 261 
on binding to PBP2, with zidebactam having lower MICs for Enterobacteriaceae and P. aeruginosa 262 
than RG6080.  The result is that -lactam combinations based on these DBOs have an in-vitro 263 
spectrum that includes many MBL-producing Enterobacteriaceae – with 80% of these organisms 264 
susceptible at 1+1 mg/L in the case of cefepime/zidebactam.  Even MBL-producing P. aeruginosa 265 
were mostly susceptible to cefepime/zidebactam at 8+8 mg/L, though MICs for A. baumannii with 266 
OXA carbapenemases were higher.  Only clinical trials and experience will reveal the extent to which 267 
these additional potentials are realised and, until then, some uncertainty will remain about the risk for 268 
selection of resistance to the antibacterial effect of these DBOs and strain-to-strain variability in the 269 
enhancer effect.  270 
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Table 1: Species and genera represented in Enterobacteriaceae groups 343 
Species Resistance mechanisms 
 ESBL AmpC KPC OXA-48-
like 
MBL a Susceptible 
controls 
E. coli 10 10 10 5 10 5 
Klebsiella 10 5 10 10 10 5 
Enterobacter/Citrobacterb 10 10 10 0 10 5 
Serratia  5    5 
Proteeaec  4 5   5 5 
 344 
a 20 with NDM enzymes and 15 with VIM types 345 
b 12 C. freundii and 33 Enterobacter spp.  346 
c13 M. morganii, 4 Providencia spp. and 2 Proteus spp.  347 
 348 
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Table 2.   MIC distributions of zidebactam by species and, for P. aeruginosa, resistance mechanism 349 
 350 
  No isolates with indicated MIC (mg/L) 
  <0.06 0.12 0.25 0.5 1 2 4 8 16 32 >32 
E. coli (n=50)  3 28 12 5 1    1   
Klebsiella spp. (n=58)   3 17 17 2 1 1 1  13 3 
Enterobacter and Citrobacter spp. (n=52)   11 20 10 2  1   1 7 
Serratia spp. (n=10)    1 1    1  7  
Proteeae (n=6)            6 
P. aeruginosa (n=50)             
-Lactam susceptible controls (n=10)       3* 5 1   1 
AmpC derepressed (n=10)        2 5 3   
MBL producers (n=10)         6 2 1 1 
Up-regulated efflux (n=10)         3 2 5  
Cystic fibrosis, mixed mechanisms (n=10)       1* 2 2 3 1 1 
A. baumannii (n=30)            30 
S. maltophilia (n=10)            10 
 351 
352 
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Table 3. MIC distributions for cefepime/zidebactam and comparator agents in relation to resistance groups and zidebactam concentrations. 353 
Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Control Enterobacteriaceae, without cephalosporin-hydrolysing -lactamases or carbapenemases (n=25) 
Cefepime - 12 7 4 2            
CPM/Zid, 0.06 1 16 3 3 2            
CPM/Zid, 0.12 9 10 1 4 1            
CPM/Zid, 0.25 13 8 3 1             
CPM/Zid, 0.5 14 11               
CPM/Zid, 1 14 11               
CPM/Zid, 2 14 11               
CPM/Zid, 4 14 11               
CPM/Zid, 8 14 11               
PIP/TAZ, 4 -    4 1  11 6 3       
Ceftazidime -  1 9 10 3 2          
CAZ/AVI, 4 - 5 4 6 7 2 1          
Meropenem - 14 8 3             
                 
Extended-spectrum -lactamase-producing Enterobacteriaceae (n=33) 
Cefepime      2 4 8 3 1 4 1 3  1 6 
CPM/Zid, 0.06   1 6 4 4 7 3 2 2 2 2     
CPM/Zid, 0.12 16 4 2 1 3 2 1 2  1 1      
CPM/Zid, 0.25 24 5 1 1    1  1       
CPM/Zid, 0.5 27 3 1 1   1          
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
CPM/Zid, 1 27 5    1           
CPM/Zid, 2 27 5   1            
CPM/Zid, 4 27 5  1             
CPM/Zid, 8 27 5 1              
PIP/TAZ, 4 -      1 6 11 6 3 1 1  1 3 
Ceftazidime -     1 3 3 2  2 3 6 9  4 
CAZ/AVI, 4 - 1 2 7 15 6 1 1         
Meropenem - 20 11 2             
                 
K. oxytoca, hyper-produced K1 -lactamase (n=5) 
Cefepime      1 3  1        
CPM/Zid, 0.06    2 1 2           
CPM/Zid, 0.12   4 1             
CPM/Zid, 0.25  5               
CPM/Zid, 0.5 3 2               
CPM/Zid, 1 3 2               
CPM/Zid, 2 3 2               
CPM/Zid, 4 3 2               
CPM/Zid, 8 3 2               
PIP/TAZ, 4               1 4 
Ceftazidime      4 1          
CAZ/AVI, 4    3 2            
Meropenem  3 2              
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
AmpC -lactamase-producing Enterobacteriaceae (n= 
Cefepime  2 2 5 4 7 6 6 3        
CPM/Zid, 0.06 0 5 7 11 3 2 4 3         
CPM/Zid, 0.12 4 14 7 2 1 4 3          
CPM/Zid, 0.25 15 9 5 2 4            
CPM/Zid, 0.5 23 10 2              
CPM/Zid, 1 25 8 2              
CPM/Zid, 2 25 8 2              
CPM/Zid, 4 25 8 2              
CPM/Zid, 8 27 6 2              
PIP/TAZ, 4     2   1  5 7 6 6 4 3 11 
Ceftazidime       1 1 1 1 5 6 9 10 1  
CAZ/AVI, 4  1 3 3 11 14 3          
Meropenem  13 14 4 4            
                 
KPC -lactamase-producing Enterobacteriaceae 
Cefepime        1 1 3 5 2 3 7 2 6 
CPM/Zid, 0.06 1    1   3 7 1 8 4 1 2 1 1 
CPM/Zid, 0.12 6    2 4 1  3 7 1 2 2 1 1  
CPM/Zid, 0.25 17 3  1 1 1   1  2  3 1   
CPM/Zid, 0.5 24 1 1  1       2  1   
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
CPM/Zid, 1 26 1 1 1         1    
CPM/Zid, 2 27 1 1       1       
CPM/Zid, 4 28 2               
CPM/Zid, 8 28 2               
PIP/TAZ, 4             1 2 2 25 
Ceftazidime         1 7 3 7 7 1 1 3 
CAZ/AVI, 4  6 1 6 5 7 3 1 1        
Meropenem       1 2 5 6 4 8 4**    
                 
OXA-48 -lactamase-producing Enterobacteriaceae 
Cefepime     3 1 3     1 5 1  1 
CPM/Zid, 0.06 1  2 1 1 2  1 2 4  1     
CPM/Zid, 0.12 5 2 2 1  1  2 1  1      
CPM/Zid, 0.25 6 5  1 2    1        
CPM/Zid, 0.5 11 2 2              
CPM/Zid, 1 11 4               
CPM/Zid, 2 11 4               
CPM/Zid, 4 12 3               
CPM/Zid, 8 12 3               
PIP/TAZ, 4              2 6 7 
Ceftazidime    1 3 2  1 3    3 2   
CAZ/AVI, 4   1 5 7 2           
Meropenem   1   3 6 2 1   2     
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
MBL-producing Enterobacteriaceae 
Cefepime     1    1 2 4 4 7 3 5 8 
CPM/Zid, 0.06     1  1 1 3 7 1 2 8 4 5 2 
CPM/Zid, 0.12 5 1  1 1 1 4 1  6 2 3 3 2 5  
CPM/Zid, 0.25 20 1   1  1  3 2 1  1  4 1 
CPM/Zid, 0.5 25   2 1 1 1 1     1  3  
CPM/Zid, 1 26  1  1 1 1 1     1  3  
CPM/Zid, 2 27    1 1 1 1     1  3  
CPM/Zid, 4 27    1 1 1 1     1  3  
CPM/Zid, 8 27    2  1 1     1  3  
PIP/TAZ, 4            1 1 1 7 25 
Ceftazidime          1   1 4 3 26 
CAZ/AVI, 4       1   1 5 3 1   24 
Meropenem        1 9 5 3 9 5 3   
                 
Control P. aeruginosa 
Cefepime     1  2 3 2 1 1      
CPM/Zid, 4 7      3          
CPM/Zid, 8 9     1a           
PIP/TAZ, 4      1  1 3 4   1    
Ceftazidime      2 2 3 2  1      
CAZ/AVI, 4      4a 2 4         
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Meropenem  1 1 2 5  1          
                 
P. aeruginosa, derepressed for AmpC -lactamase 
Cefepime         1 1 2 5  1   
CPM/Zid, 4 1      1  2 4 1 1     
CPM/Zid, 8 7      1 1   1      
PIP/TAZ, 4            1 1 1 3 4 
Ceftazidime          1 1 1 4 2 1  
CAZ/AVI, 4       1 2 3 3 1      
Meropenem      2 6 1 1        
                 
P. aeruginosa, with MBLs 
Cefepime           1 2  1 1 5 
CPM/Zid, 4          1  1 2 1 1 4 
CPM/Zid, 8 6     2a         1 1 
PIP/TAZ, 4            1 4  2 3 
Ceftazidime            2 1 1  6 
CAZ/AVI, 4            2 1 1  6 
Meropenem            2 1 7 b   
                 
P. aeruginosa, with upregulated efflux 
Cefepime          2 6 2     
CPM/Zid, 4      1a    5 4      
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Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
CPM/Zid, 8 2      1 1 1 3 2      
PIP/TAZ, 4            4 2 1 2 1 
Ceftazidime          5 1 2 2    
CAZ/AVI, 4         1 8 1      
Meropenem           1 6 3    
P. aeruginosa, cystic fibrosis isolates 
Cefepime             2 1 5 2 
CPM/Zid, 4 3     1a      2 2 2   
CPM/Zid, 8 5     2a  2     1    
PIP/TAZ, 4          1     2 7 
Ceftazidime               4 6 
CAZ/AVI, 4          3  1 2 1 3  
Meropenem          2 4 2 2    
                 
A. baumannii, susceptible controls 
Cefepime       2 2 1        
CPM/Zid, 4       1 3 1        
CPM/Zid, 8        5         
PIP/TAZ, 4      4 a    1       
Ceftazidime       2 2 1        
CAZ/AVI, 4        2 2 1       
Meropenem     4 1           
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A. baumannii, OXA carbapenemases 
Antibiotic and 
[inhibitor], mg/L 
Inhibited by 
zidebactam 
alone (n) 
Number of isolates with indicated MIC (mg/L) 
<0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Cefepime           3 12 4   1 
CPM/Zid, 4          2 10 5 3    
CPM/Zid, 8        1  2 9 6 2    
PIP/TAZ, 4            2 0 1 4 13 
Ceftazidime          1 2  2 7 2 6 
CAZ/AVI, 4         1 1 6 5 2 1  4 
Meropenem         1 1 1 11 4 2 b   
                 
A. baumannii, metallo (NDM) carbapenemases 
Cefepime                5 
CPM/Zid, 4               1 4 
CPM/Zid, 8               1 4 
PIP/TAZ, 4                5 
Ceftazidime                5 
CAZ/AVI, 4                5 
Meropenem             1 4   
S. maltophilia 
Cefepime        1  2 2 3 2    
CPM/Zid, 4       1 1 3 2 2 1     
CPM/Zid, 8      1a  1 3 2 2 1     
PIP/TAZ, 4           1  3  1 5 
Ceftazidime      1  1  1 1 1 1 1 2 1 
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CAZ/AVI, 4      1  1  1 1 1 2  3  
Meropenem             1 9 b   
 354 
* MIC < indicated value; **MIC >indicated value;  Abbreviations: CAZ+AVI, ceftazidime/avibactam, CPM-Zid, cefepime/zidebactam; PIP+TAZ Piperacillin-tazobactam 355 
  356 
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Table 4: Combination behaviour against Enterobacteriaceae with zidebactam MICs >16 mg/L and cefepime >2 mg/L  357 
Specimen ID Species 
MIC Zidebactam 
(mg/L) 
Cefepime MIC (mg/L) with zidebactam at: 
0 0.06 0.12 0.25 0.5 1 2 4 8 
SE01046 S. marcescens, AmpC >32 2 1 0.25 0.25 <0.03 <0.03 <0.03 <0.03 <0.03 
H053420099  K. pneumoniae,  CTX-M 9 gp >32 64 32 16 8 0.125 <0.03 <0.03 <0.03 <0.03 
NCTC 13465 K. pneumoniae,  CTX-M-25 >32 16 1 0.5 0.06 <0.03 <0.03 <0.03 <0.03 <0.03 
Mei 1 K. pneumoniae,  ESBL >32 2 0.06 0.125 <0.03 <0.03 <0.03 <0.03 <0.03 <0.03 
SE06031 M. morganii, CTX-M 1 group >32 4 0.25 0.06 <0.03 <0.03 <0.03 <0.03 <0.03 <0.03 
H053460141 Proteus spp., ESBL >32 >256 32 8 2 1 0.5 0.25 0.125 0.06 
LN09056 P. mirabilis, ESBL >32 >256 1 0.25 0.125 0.06 <0.03 <0.03 <0.03 <0.03 
H092260700 Klebsiella spp., OXA-48 + ESBL >32 64 8 2 0.25 0.06 <0.03 <0.03 <0.03 <0.03 
H112860135 Klebsiella spp., OXA-48 + ESBL >32 >256 8 2 0.125 0.06 <0.03 <0.03 <0.03 <0.03 
H131480242 M. morganii, ESBL >32 >256 >256 >256 256 128 <0.03 <0.03 <0.03 <0.03 
H124240625 K. pneumoniae, KPC + SHV >32 256 128 64 64 32 0.125 0.06 <0.03 <0.03 
H114600525 E. aerogenes, KPC >32 64 16 8 4 0.06 <0.03 <0.03 <0.03 <0.03 
H113980340 K. pneumoniae,  NDM, Azt-R >32 256 64 32 8 0.25 0.25 0.25 0.25 0.25 
H112240413 K. pneumoniae, VIM, Azt-R >32 4 2 2 1 0.5 0.5 0.5 0.5 0.25 
H130680324 E. coli, NDM, Azt-R 16 >256 256 256 256 256 256 256 256 256 
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H092540314 M. morganii, NDM, Azt-I >32 64 8 8 4 1 1 1 1 1 
H123140552 P. rettgeri, NDM, Azt-R >32 >256 >256 256 256 256 256 256 256 256 
H123560843 P. rettgeri, NDM, VEB, CMY-14 Azt-R >32 >256 256 256 256 256 256 256 256 256 
H124880510 P. stuartii, NDM, Azt-S >32 16 16 16 16 2 2 2 2 2 
H124880511 P. rettgeri, NDM, Azt-S >32 64 64 64 64 64 64 64 64 64 
 358 
Azt-S/I/R: aztreonam susceptible, intermediate or resistant, based on prior testing by BSAC methodology and taken as an indicator of ESBL/AmpC presence 359 
or absence in MBL producing isolate360 
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Figure 1.  Structure of zidebactam  361 
 362 
Figure 2.  Killing curves for Gram-negative bacteria with NDM carbapenemases by cefepime, zidebactam 363 
and their combinations.  Panel (a) K. pneumoniae H113840625 with MICs cefepime 256 mg/L, 364 
zidebactam 0.25 mg/L, meropenem 32 mg/L; (b) K. pneumoniae H113980340 with MICs cefepime 256 365 
mg/L, zidebactam >32 mg/L, meropenem 32 mg/L;  (c) E. coli H131020913 with  MICs cefepime >256 366 
mg/L, zidebactam 0.25 mg/L , meropenem 64 mg/L; (d) E. coli H130480324 with  MICs cefepime >256 367 
mg/L, zidebactam 16 mg/L, meropenem 32 mg/L; (e and f) P. aeruginosa H130680310 with MICs 368 
cefepime >256 mg/L, zidebactam 8 mg/L cefepime and  meropenem >64 mg/L; (g and h) P. aeruginosa 369 
H131800691 with MICs cefepime >256 mg/L, zidebactam 32 mg/L cefepime and  meropenem 64 mg/L 370 
and (i), A. baumannii H104940508 with OXA-23 carbapenemase  with MICs cefepime >256 mg/L, 371 
zidebactam >32 mg/L and  meropenem 32 mg/L. 372 
373 
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